An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066/ ABBV-066/Risankizumab Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004972/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to investigate long-term safety and efficacy of BI 655066/ABBV-066/risankizumab, in patients with moderate to severe chronic plaque psoriasis, during open-label treatment.
提供机构：
Vivli
创建时间：
2019-11-13
